Corrigendum: Genomic Assays in Node Positive Breast Cancer Patients: A Review

Corrigendum: Genomic Assays in Node Positive Breast Cancer Patients: A Review

Bibliographic Details
Main Authors:	Maroun Bou Zerdan, Maryam Ibrahim, Clara El Nakib, Rayan Hajjar, Hazem I. Assi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-04-01
Series:	Frontiers in Oncology
Subjects:	breast cancer oncotype Dx MammaPrint PAM50 endopredict breast cancer index
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.686355/full

Similar Items

The evolution of gene expression profiling in breast cancer – A narrative review
by: Banushree Chandrasekhar Srinivasamurthy
Published: (2023-01-01)

Clinical Utility of Genomic Assay in Node-Positive Early-Stage Breast Cancer
by: Mehrnoosh Pauls, et al.
Published: (2022-07-01)

Genomic testing in international guidelines
by: Peter Kern, et al.
Published: (2013-10-01)

Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline
by: Phillip Blanchette, et al.
Published: (2022-04-01)

The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
by: Ettienne J. Myburgh, et al.
Published: (2021-10-01)

The Role of Multigene Assays Adjuvant Treatment Decision for Early-Stage Breast Cancer
by: Cornelia NITIPIR, et al.
Published: (2020-06-01)

Genetic and clinical landscape of ER + /PR- breast cancer in China
by: Danian Dai, et al.
Published: (2023-12-01)

Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients
by: Bo Pan, et al.
Published: (2023-11-01)

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
by: Hatem Soliman, et al.
Published: (2020-01-01)

Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling
by: S Aggarwal, et al.
Published: (2018-01-01)

New Approaches in Breast Cancer Radiotherapy
by: Niyazi Volkan Demircan, et al.
Published: (2024-01-01)

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
by: Thomas M. Schwedhelm, et al.
Published: (2020-09-01)

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
by: Xiaofu Zhu, et al.
Published: (2021-02-01)

Spotlight on the utility of the Oncotype DX® breast cancer assay
by: Siow ZR, et al.
Published: (2018-02-01)

The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center
by: Stephane Thibodeau, et al.
Published: (2019-07-01)

Lymphovascular invasion is an independent prognostic factor in breast cancer irrespective of axillary node metastasis and molecular subtypes
by: Suk Jun Lee, et al.
Published: (2023-11-01)

Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
by: Evelien Schaafsma, et al.
Published: (2021-07-01)

Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
by: T. M. Aherne, et al.
Published: (2020-04-01)

Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients
by: Daniele Generali, et al.
Published: (2024-11-01)

The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx
by: Michał Jarząb, et al.
Published: (2024-10-01)

The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes
by: Jun Wang, et al.
Published: (2018-12-01)

Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis
by: Ping Zhou, et al.
Published: (2020-12-01)

The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1–3 node positive breast cancer
by: Yogeshkumar Malam, et al.
Published: (2022-08-01)

Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up
by: Cihan Uras, et al.
Published: (2022-11-01)

Corrigendum: Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center
by: Dániel Deme, et al.
Published: (2024-07-01)

Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle- Income Country, Turkey: Results of a Prospective Multicenter Study
by: Vahit Özmen, et al.
Published: (2019-07-01)

Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array
by: Hans-Ullrich Völker, et al.
Published: (2018-08-01)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
by: Michael Crager, et al.
Published: (2022-11-01)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer
by: Berdunov V, et al.
Published: (2022-09-01)

Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center
by: Dániel Deme, et al.
Published: (2024-04-01)

MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification
by: Ünal Ç, et al.
Published: (2023-09-01)

Assessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorization
by: Çağlar Ünal, et al.
Published: (2023-10-01)

A 10 year service evaluation of the survival of 439 patients with early oestrogen receptor positive breast cancer who underwent initial OncotypeDX ® testing to guide adjuvant chemotherapy decisions
by: Asma Munir, et al.
Published: (2023-01-01)

Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany
by: M.P. Lux, et al.
Published: (2022-01-01)

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers
by: Pascale A. Cohen, et al.
Published: (2019-05-01)

Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
by: McVeigh TP, et al.
Published: (2017-05-01)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test from a US Societal Perspective
by: Berdunov V, et al.
Published: (2024-06-01)

Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center
by: John Loggie, et al.
Published: (2024-06-01)

Developing a clinical-pathologic model to predict genomic risk of recurrence in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative, node negative breast cancer
by: Atul Batra, et al.
Published: (2021-01-01)

The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer
by: Atilla Soran, et al.
Published: (2020-04-01)